Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate EyePoint Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding EyePoint Pharmaceuticals, Inc.’s stock price such as:

• EyePoint Pharmaceuticals, Inc.’s current stock price and volume
• Why EyePoint Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for EYPT from analysts
• EYPT’s stock price momentum as measured by its relative strength

About EyePoint Pharmaceuticals, Inc. (EYPT)

Before we jump into EyePoint Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Want to learn more about EyePoint Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about EyePoint Pharmaceuticals, Inc..

EyePoint Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of January 22, 2025, 4:00 PM, CST, EyePoint Pharmaceuticals, Inc.’s stock price was $8.720.

EyePoint Pharmaceuticals, Inc. is up 15.8% from its previous closing price of $7.530.

During the last market session, EyePoint Pharmaceuticals, Inc.’s stock traded between $7.675 and $8.740. Currently, there are approximately 54.45 million shares outstanding for EyePoint Pharmaceuticals, Inc..

EyePoint Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

EyePoint Pharmaceuticals, Inc. Stock Price History

EyePoint Pharmaceuticals, Inc.’s (EYPT) price is currently up 17.05% so far this month.

During the month of January, EyePoint Pharmaceuticals, Inc.’s stock price has reached a high of $9.500 and a low of $6.985.

Over the last year, EyePoint Pharmaceuticals, Inc. has hit prices as high as $30.990 and as low as $6.900. Year to date, EyePoint Pharmaceuticals, Inc.’s stock is up 17.05%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused EyePoint Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of January 21, 2025,, no analysts have changed their rating of EyePoint Pharmaceuticals, Inc.’s stock over the last month.

Additionally, you'll want to evaluate EyePoint Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on EyePoint Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

EyePoint Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about EyePoint Pharmaceuticals, Inc. (EYPT) by visiting AAII Stock Evaluator.

Relative Price Strength of EyePoint Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 21, 2025, EyePoint Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -25.30%, which translates to a Momentum Score of 7 and is considered to be Very Weak.

Want to learn more about how EyePoint Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

EyePoint Pharmaceuticals, Inc. Stock Price: Bottom Line

As of January 22, 2025, EyePoint Pharmaceuticals, Inc.’s stock price is $8.720, which is up 15.8% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like EyePoint Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.